纳武利尤单抗联合伊匹木单抗加两周期铂类双药化疗对比单独铂类双药化疗用于美国IV期或复发性非小细胞肺癌一线治疗的成本效果分析数据集

数据集获取（Figshare）

• 源站标题：Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States
• DOI：10.6084/m9.figshare.20004815.v1
• 发布日期：2022-06-06
• 文件数：3 个
• 文件总体积：1.91 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-effectiveness_analysis_of_nivolumab_plus_ipilimumab_plus_two_cycles_of_platinum-doublet_chemotherapy_versus_platinum-doublet_chemotherapy_alone_for_first-line_treatment_of_stage_IV_or_recurrent_non-small_cell_lung_cancer_in_the_United_/20004815

命令行下载

curl -L -o "Polyzoi et al. CEA US NIVO CM9LA_SUPPLEMENT_281021.docx" "https://ndownloader.figshare.com/files/35604647"
curl -L -o "Supp Figure 1.eps" "https://ndownloader.figshare.com/files/35604650"
curl -L -o "Supp Figure 2.eps" "https://ndownloader.figshare.com/files/35604653"

文件清单

• Polyzoi et al. CEA US NIVO CM9LA_SUPPLEMENT_281021.docx（449.63 KB）
• Supp Figure 1.eps（827.81 KB）
• Supp Figure 2.eps（631.34 KB）

文件总体积 1.91 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This economic analysis evaluated the cost-effectiveness of nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of platinum-doublet chemotherapy (PDC) compared with four cycles of PDC as first-line treatment for patients with advanced NSCLC in the United States (US).
A partitioned survival model was constructed with three mutually exclusive health states: progression free, progressed disease, and death. The analysis was conducted from a US healthcare payer perspective, using a time horizon of 25 years. Costs and outcomes were discounted at 3% annually. Survival outcomes from CheckMate 9LA were extrapolated with longer follow-up data from CheckMate 227 Part 1 (NIVO + IPI) and validated against data from other relevant clinical trials and real-world registries. Health-related quality of life utility values were derived from EQ-5D-3L data collected in CheckMate 9LA. US-specific costs (2020 dollars) were used for disease management; drug acquisition, administration, and monitoring; end-of-life care; adverse events; and subsequent treatments. Model outcomes included life years (LYs) gained, quality-adjusted LYs (QALYs) gained, and incremental cost-effectiveness ratio (ICER) for NIVO + IPI + PDC versus PDC. Sensitivity and scenario analyses were conducted.
NIVO + IPI + PDC was associated with higher projected health benefits than PDC, including gains in LYs (3.71 vs 1.89) and QALYs (2.86 vs 1.37), and higher costs ($317,581 vs $119,909). The ICER was $132,960/QALY gained. NIVO + IPI + PDC had a 78–100% probability of being cost-effective at a willingness-to-pay threshold of $150,000–$250,000/QALY. Sensitivity and scenario analyses indicated that the results were robust to changes in key parameters.
The inherent limitation in extrapolating clinical trial data was mitigated using data from the more mature CheckMate 227 Part 1 trial and validating the outcomes against data from other relevant trials and real-world registries.
NIVO + IPI + PDC (two cycles) provides a new first-line treatment option for patients with advanced NSCLC that is cost-effective within a range considered acceptable in the US.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.20004815.v1（source: https://tandf.figshare.com/articles/dataset/Cost-effectiveness_analysis_of_nivolumab_plus_ipilimumab_plus_two_cycles_of_platinum-doublet_chemotherapy_versus_platinum-doublet_chemotherapy_alone_for_first-line_treatment_of_stage_IV_or_recurrent_non-small_cell_lung_cancer_in_the_United_/20004815）。